.png){kind=icon}
.png){kind=icon}
Return
Metabolites in the tumor microenvironment: Key drivers of immune cell fate and function as therapeutic targets in cancer
.png){kind=icon}
PRE
AI
X
C
Y
X
N
X
X
DOI：10.1016/j.bbcan.2026.189590.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Tumor cells employ multiple strategies to evade immune detection, largely facilitated by the immunosuppressive tumor microenvironment (iTME). This environment not only hinders therapeutic efficacy but also drives metabolic reprogramming of tumor cells, resulting in localized nutrient deprivation and the accumulation of immunomodulatory metabolites. Metabolites such as lactic acid and adenosine accumulate under hypoxic and poorly perfused conditions, directly altering immune cell function and promoting tumor immune escape. Consequently, these metabolites have emerged as promising therapeutic targets in cancer immunotherapy. In this review, we systematically examine how TME-derived metabolites influence diverse immune cell populations and summarize current clinical progress in targeting their production and signaling pathways for anticancer treatment.
Keywords:
Tumor microenvironment
Immune cell function
Metabolic reprogramming
Immunomodulatory metabolites
Cancer immunotherapy
Journal
B
IF:
0
Papers:
105
Citations:
0
Organization
Cited Papers